Evidence mapPaperPMID 35819749Full record

ReviewJournal of nephrology2022

On the importance of the interplay of residual renal function with clinical outcomes in end-stage kidney disease.

Cem Tanriover, Duygu Ucku, Carlo Basile, Katherine R Tuttle, Mehmet Kanbay

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Shared decision making in elderly patients with kidney failure.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Review
  11. Article
  12. Review
  13. Review
  14. A new immune disease: systemic hypertension.Clinical kidney journal · 2023
    Review
  15. Review
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Cem TanrioverDepartment of Medicine, Koc University School of Medicine, Istanbul, Turkey.
Duygu UckuDepartment of Medicine, Koc University School of Medicine, Istanbul, Turkey.
Carlo BasileAssociazione Nefrologica Gabriella Sebastio, Martina Franca, Italy. basile.miulli@libero.it.ORCID 0000-0001-8152-5471
Katherine R TuttleDivision of Nephrology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-2235-0103
Mehmet KanbayDivision of Nephrology, Department of Medicine, Koc University School of Medicine, Istanbul, Turkey.ORCID 0000-0002-1297-0675
Koç University · TRAssociazione Italiana Di Oncologia Medica · ITUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) is one of the most important public health concerns of the century, and is associated with high rates of morbidity, mortality and social costs. CKD evolving towards end-stage kidney disease (ESKD) is on the rise resulting in a greater number of patients requiring peritoneal dialysis (PD) and hemodialysis (HD). The aim of this manuscript is to review the current literature on the interplay of residual renal function (RRF) with clinical outcomes in ESKD. The persistence of RRF is one of the most important predictors of decreased morbidity, mortality, and better quality of life in both PD and HD patients. RRF contributes to the well-being of ESKD patients through various mechanisms including higher clearance of solutes, maintenance of fluid balance, removal of uremic toxins and control of electrolytes. Furthermore, RRF has beneficial effects on inflammation, anemia, malnutrition, diabetes mellitus, obesity, changes in the microbiota, and cardiac diseases. Several strategies have been proposed to preserve RRF, such as blockade of the renin-angiotensin-aldosterone system, better blood pressure control, incremental PD and HD. Several clinical trials investigating the issue of preservation of RRF are ongoing. They are needed to broaden our understanding of the interplay of RRF with clinical outcomes in ESKD.

Indexed as

Kidney Failure, ChronicPeritoneal DialysisDisease ProgressionHumansKidneyQuality of LifeRenal DialysisChronic kidney diseaseEnd-stage kidney diseaseHemodialysisPeritoneal dialysisResidual renal function

Identifiers

PMID35819749
OpenAlexW4285022392

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.